0016-3813 0016-3813 S0016-38132022000900001 10.24875/gmm.m21000597 México México México Bolivia México México México México México México México México México México México México México México México México México México México México México México México México México México México México México México México México República Dominicana México 00 00 2022 00 00 2022 158 spe M1 M51

1 2016 374 2209-21 2 2009 106 12944 3 2009 106 12950 4 Cancer Genome Atlas Research Network 2013 368 2059 5 2015 373 1136-52 6 2020 27 81 7 2020 20 6 6 e295-303 8 2016 152 66-77 9 2007 92 1389-98 10 2001 112 109-17 11 2011 117 2137-45 12 2018 13 2014 371 2488-98 14 2014 371 2477-87 15 2014 20 12 12 1472-8 16 2005 104 788-93 17 2017 141 1342 18 2019 7th ed 580-92 19 2020 42 1 1 3-15 20 2016 127 20 20 2391-405 21 2010 115 453-74 22 2019 37 3 3 239-53 23 1976 33 4 4 451-8 24 2017 129 4 4 424-47 25 2016 23 144-9 26 2017 71 1 1 20-4 27 2015 33 31 31 3641-9 28 2018 23 38 38 555-73 29 2018 93 10 10 1267-91 30 For the Study Alliance Leukaemia (SAL) 2012 13 2 2 207-14 31 2020 42 3-15 32 2009 36 249-129 33 2010 28 5 5 808-14 34 2018 10 5 5 555800 35 2013 31 3360-8 36 2014 32 3 3 219-28 37 1996 88 8 8 2841-51 38 2012 366 12 12 1079-89 39 2002 3 283-9 40 2017 377 454-64 41 2019 133 8 8 840 42 2014 15 9 9 986-96 43 2009 35 485-6 44 2005 3 572-90 45 2007 109 1114-24 46 2015 126 291-9 47 2013 27 1 1 75-81 48 2020 135 24 24 2137-45 49 2019 33 2795-804 50 2009 301 22 22 2349-61 51 2019 54 10 10 1525-52 52 2021 19 1 1 16-27 53 2010 116 1 1 129-39 54 2008 10 1 1 42-6 55 2018 10 340 340 1-12 56 2020 188 1 1 129-46 57 2003 102 4 4 1232-40 58 2019 141 3 3 164-75 59 2017 55 97-104 60 2018 93 6 6 769-77 61 2019 3 12 12 1826-36 62 2020 95 8 8 892-9 63 1999 105 799 64 2000 108 1 1 99-104 65 2009 27 27 27 4570-7 66 2013 122 24 24 3871-8 67 2012 47 2 2 203-11 68 2015 126 23 23 LBA-8 69 2016 128 6 6 763-73 70 1988 6 4 4 583-7 71 2014 93 8 8 1391-400 72 2014 20 2 2 168-72 73 2012 97 9 9 e34-5 74 2019 94 11 11 1254-65 75 2010 116 23 23 5420-31 76 2015 169 5 5 756-9 77 2018 132 661 661 78 2021 137 13 13 1792-803 79 2018 53 11 11 1379-89 80 2019 54 1 1 6-16 81 2019 60 11 11 2733-43 82 2020 105 1 1 47-58 83 2019 186 5 5 767-76 84 2018 131 1275-91 85 On behalf of the EuroFlow Consortium 2012 26 1938-43 86 2012 26 9 9 1908-75 87 2009 9 Suppl 3 Suppl 3 S281-5 88 2015 373 12 12 1136-52 89 2010 116 17 17 3147-56 90 2020 135 2 2 85-96 91 2013 121 7 7 1077-82 92 2020 136 9 9 1023-32 93 2020 96 1-6 94 2005 23 9 9 1969-78 95 2021 106 3 3 894-8 96 2020 2020 1 1 41-50 97 2010 116 21 21 5012-21 98 2009 84 11 11 733-7 99 2007 80 2 2 115-26 100 1998 58 2 2 105-9 101 1997 99 4 4 939-44 102 1991 9 7 7 1210-4 103 2012 118 1 1 112-7 104 2017 9 97-102 105 2018 140 114-20 106 2019 133 15 15 1630-43 107 2004 45 7 7 1365-68 108 2013 30 625 109 2016 127 20 20 2375-90 110 2000 96 4 4 1287 111 1982 50 2 2 201 112 1984 76 5 5 827 113 2019 141 232-44 114 1992 80 2 2 470-7 115 2013 37 9 9 1021-6 116 1999 93 10 10 3167 117 1997 337 1021-8 118 2010 115 5137-46 119 2013 121 11 11 1935-43 120 2015 16 13 13 1295-305 121 2004 101 15 15 5328-35 122 2000 96 4 4 1247-53 123 2013 369 2 2 111-21 124 2006 24 36 36 5703-10 125 2009 27 4 4 504-10 126 2002 99 11 11 4222-4 127 2010 115 1690-6 128 2015 94 8 8 1347-56 129 2009 113 9 9 1875-91 130 2010 116 20 20 4274-83 131 2013 121 8 8 1432-5 132 2014 124 6 6 936-45 133 2015 168 6 6 904-8 134 2015 13 1 1 19-22 135 2017 129 19 19 2705-9 136 2016 23 2 2 121-6 137 2017 129 13 13 1855 138 1999 340 13 13 994 139 2018 131 8 8 845-54 140 2020 94 106356 141 1998 92 8 8 2712-8 142 2011 3 1 1 e2011059 143 2009 113 4 4 775-83 144 2014 123 18 18 2777-82 145 2016 128 34 146 2016 128 591 147 2016 128 102 148 2017 1 17 17 1312-23 149 2016 122 304-11 150 2020 40 5 5 2917-24 151 2018 36 2684-92 152 Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia 153 2017 17 852 154 2018 75 29-35 155 2019 102 5 5 437-41 156 2019 133 1 1 7-17 157 US Food and Drug Administration 2018 158 2003 47 617-21 159 1998 48 593-8 160 2015 170 487-95 161 2019 10 1 1 3-9 162 2007 92 1230-7 163 2005 44 989-1008 164 2015 39 512-9 165 2007 5 61-75 166 2012 286 283-6 167 2015 212 830-1 168 2004 5 283-91 169 2015 35 1052-62 170 2015 125 197-203 171 2014 210 e1-7 172 2012 30 395-405 173 1992 166 1515-28 174 2012 26 117-22 175 2015 49 48-68 176 2010 2 278-86 177 2004 15 146-50 178 2015 170 441-2 179 2014 123 974-84 180 2018 9 6 6 659-64 181 2016 27 5 5 111-8 182 2018 36 1442-53 183 2016 14 7 7 882-913 184 2013 119 107-14 185 2005 68 suppl 1 suppl 1 3-11 186 2017 36 283-99 187 2020 2020 1 1 527-32 188 2020 46 3 3 238-44 189 2018 10 7724 190 2011 29 4189 191 2007 10 4 4 919-22 192 2018 55 1 1 82-88.e1 193 2017 12 300-8 194 2018 32 1 1 79-105 195 2019 42 1-2 1-2 25-30 196 2015 2015 471-8 197 2011 4 1 1 81-93 198 2011 29 9 9 1151-8 199 2011 6 243-59 200 2020 4 15 15 3528-49 201 2017 40 6 6 E31-8 202 2017 22 4 4 361-8 203 2015 1 204 2020 60 4 4 754-64 205 1998 33-44 206 2010 7 1 1 193-205 207 2018 21 7 7 1024-37 208 2019 60 3 3 278-84